AR066395A1 - Reovirus que tienen secuencias modificadas - Google Patents

Reovirus que tienen secuencias modificadas

Info

Publication number
AR066395A1
AR066395A1 ARP080101017A ARP080101017A AR066395A1 AR 066395 A1 AR066395 A1 AR 066395A1 AR P080101017 A ARP080101017 A AR P080101017A AR P080101017 A ARP080101017 A AR P080101017A AR 066395 A1 AR066395 A1 AR 066395A1
Authority
AR
Argentina
Prior art keywords
reovirus
modified
modified sequences
nucleic acid
well
Prior art date
Application number
ARP080101017A
Other languages
English (en)
Spanish (es)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR066395A1 publication Critical patent/AR066395A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP080101017A 2007-03-12 2008-03-12 Reovirus que tienen secuencias modificadas AR066395A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US98956807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
AR066395A1 true AR066395A1 (es) 2009-08-19

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101017A AR066395A1 (es) 2007-03-12 2008-03-12 Reovirus que tienen secuencias modificadas

Country Status (16)

Country Link
US (5) US7803385B2 (enExample)
EP (2) EP2952583A1 (enExample)
JP (1) JP5577103B2 (enExample)
KR (1) KR101647843B1 (enExample)
CN (1) CN103710359A (enExample)
AR (1) AR066395A1 (enExample)
AU (1) AU2008226291B2 (enExample)
CA (1) CA2678721C (enExample)
DK (1) DK2132315T3 (enExample)
ES (1) ES2548442T3 (enExample)
IL (4) IL200353A (enExample)
MX (2) MX2009009598A (enExample)
SG (1) SG191602A1 (enExample)
TW (1) TW200904979A (enExample)
WO (1) WO2008110004A1 (enExample)
ZA (1) ZA200905951B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
SG191602A1 (en) 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
AU2008316276A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
MX2010014555A (es) * 2008-06-26 2011-04-27 Ceva Sante Animale Sa Reoviridae aviar unico.
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
EP2482825B1 (en) 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Piscine reovirus diagnostic compositions
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) * 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
ES2796950T3 (es) 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
WO2017141942A1 (ja) 2016-02-16 2017-08-24 国立大学法人大阪大学 線維化を治療するための医薬組成物
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
US20220193220A1 (en) * 2019-05-03 2022-06-23 Kansas State University Research Foundation Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs
CN116917468A (zh) * 2020-12-22 2023-10-20 百洛克株式会社 新型修饰的呼肠孤病毒及其用途
JP2024500164A (ja) * 2020-12-22 2024-01-04 バイロキュア インコーポレイテッド 新規な改変レオウイルス及びその用途
US20250154204A1 (en) * 2021-09-24 2025-05-15 Virocure, Inc. Novel reovirus-based vaccine platform and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
ES2445704T3 (es) 2000-11-09 2014-03-04 Oncolytics Biotech Inc. Métodos para el tratamiento de trastornos celulares proliferativos
WO2002043647A2 (en) 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
IL157304A0 (en) 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US20100086522A1 (en) 2006-07-18 2010-04-08 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
SG191602A1 (en) 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CA2819236A1 (en) * 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX373096B (es) * 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.

Also Published As

Publication number Publication date
KR101647843B1 (ko) 2016-08-11
US10596260B2 (en) 2020-03-24
JP5577103B2 (ja) 2014-08-20
AU2008226291A2 (en) 2009-10-08
IL221701A0 (en) 2012-10-31
AU2008226291A1 (en) 2008-09-18
CA2678721C (en) 2018-02-13
HK1132761A1 (en) 2010-03-05
US11246930B2 (en) 2022-02-15
AU2008226291B2 (en) 2014-01-16
JP2010520758A (ja) 2010-06-17
US20090035278A2 (en) 2009-02-05
US7803385B2 (en) 2010-09-28
US20110020288A1 (en) 2011-01-27
US20200237917A1 (en) 2020-07-30
US20140186301A1 (en) 2014-07-03
TW200904979A (en) 2009-02-01
MX346950B (es) 2017-04-06
ES2548442T3 (es) 2015-10-16
EP2132315A1 (en) 2009-12-16
US10039827B2 (en) 2018-08-07
EP2132315B1 (en) 2015-07-15
IL221700A0 (en) 2012-10-31
EP2132315A4 (en) 2011-10-05
ZA200905951B (en) 2010-11-24
IL221702A0 (en) 2012-10-31
SG191602A1 (en) 2013-07-31
MX2009009598A (es) 2009-09-21
CN103710359A (zh) 2014-04-09
US20080226602A1 (en) 2008-09-18
WO2008110004A1 (en) 2008-09-18
EP2952583A1 (en) 2015-12-09
IL200353A (en) 2017-07-31
US20180344853A1 (en) 2018-12-06
US8691241B2 (en) 2014-04-08
DK2132315T3 (en) 2015-10-19
IL200353A0 (en) 2011-08-01
CA2678721A1 (en) 2008-09-18
KR20090125103A (ko) 2009-12-03

Similar Documents

Publication Publication Date Title
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MX346950B (es) Reovirus que tienen secuencias modificadas.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
GT201200189A (es) Antagonistas de pcsk9
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
BRPI0817811A2 (pt) Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином

Legal Events

Date Code Title Description
FB Suspension of granting procedure